2300982-44-7

Usage

Uses

Used in Pharmaceutical Industry:
1-(5-4-amino-7-ethyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl-2,3-dihydro-1H-indol-1-yl)-2-[3-(trifluoromethoxy)phenyl]ethan-1-one is used as a potential pharmaceutical drug or precursor for the development of new medications. Its complex structure and the presence of various functional groups suggest that it may interact with biological systems in unique ways, making it a promising candidate for targeting specific receptors or enzymes relevant to certain diseases or conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 1-(5-{4-amino-7-ethyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2,3-dihydro-1H-indol-1-yl)-2-[3-(trifluoromethoxy)phenyl]ethan-1-one is used as a subject of study to understand its interactions with biological systems. The insights gained from such research can contribute to the design and development of new drugs with improved efficacy and selectivity.

Upstream product

• 1500-85-2 7-deazaadenine 
• 163622-50-2 4-amino-5-iodo-7H-pyrrolo[2,3‐d]pyrimidine 
• 1151653-42-7 7-ethyl-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine 
• 351-35-9 3-(trifluoromethyl)phenylacetic acid 
• 837392-67-3 1,1-dimethylethyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-indole-1-carboxylate 
• 261732-38-1 tert-butyl 5-bromoindoline-1-carboxylate 
• 22190-33-6 5-bromoindoline 
• 203302-97-0 2-(3-(trifluoromethoxy)phenyl)acetic acid 

Relevant academic research and scientific papers

4-aminopyrrolopyrimidine derivative and preparation method and application thereof

The invention relates to a 4-aminopyrrolopyrimidine derivative and a preparation method and application thereof, and belongs to the field of medicines. The invention provides a compound shown as a formula I or pharmaceutically acceptable salt thereof. The

Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model

We herein report the structural optimization and structure-activity relationship studies of 5-(2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as a new class of receptor-interacting protein kinase 1 (RIPK1) inhibitors. Among all obtained RIPK1 inhibitors, 1-(5-{4-amino-7-ethyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2,3-dihydro-1H-indol-1-yl)-2-[3-(trifluoromethoxy)phenyl]ethan-1-one (22b) is the most active one. This compound potently inhibited RIPK1 with a binding affinity (KD) of 0.004 μM and an enzymatic IC50 value of 0.011 μM and also showed good kinase selectivity. It could efficiently protect cells from necroptosis and attenuate the necrotic cell death of vascular endothelial cells induced by tumor cells both in vitro and in vivo. Importantly, compound 22b exhibited excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model. It also displayed favorable pharmacokinetic properties. Collectively, 22b could be a promising agent for preventing tumor metastasis.